Plain-English translation of NCT06963684 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This study doesn't follow the usual testing phases — it may be an observational study or a different type of research.
The GLASS Study is testing a laser procedure called Direct Selective Laser Trabeculoplasty (DSLT) to help lower eye pressure in people with glaucoma or high eye pressure. In this study, one of your eyes will receive the laser treatment twice (once at the start, once after 3 months), while the other eye receives it just once. Researchers want to see if the extra treatment in one eye helps keep pressure lower for longer.
Many people with early glaucoma need medication to control their eye pressure and prevent vision loss, but some prefer laser treatment instead. This study is trying to figure out whether doing the laser treatment twice works better than doing it just once, which could help more patients avoid or delay the need for daily eye drops.
You likely qualify if…
You likely don't qualify if…
You will have laser treatment in both eyes at your first visit. Three months later, one randomly selected eye will receive the laser treatment again, while the other eye serves as a comparison. You will return for follow-up visits at 4, 6, 9, and 12 months after your first treatment. At each visit, the study team will measure your eye pressure, check your vision, examine your eyes, and monitor for any side effects using various eye tests and imaging.
AI-generated summary from trial data · Jun 5, 2026 · Not medical advice
United States